Protocol Ledger

NCT06609226 · Phase III · RECRUITING

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

Interventional Phase III clinical trial protocol NCT06609226 sponsored by Novo Nordisk in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-01-10 Enrollment: 480 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06609226
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)480 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06609226
Protocol FieldVerified Registry Value
NCT IdentifierNCT06609226
Consolidated Lead SponsorNovo Nordisk
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment480 participants (ESTIMATED)
Registered Start Date2025-01-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06609226
Hospital Research SiteLocationSite Profile
Children's Hospital Los AngelesLos Angeles, CAOpen Hospital Dossier ->
UCI Health and Chao Family Comprehensive Cancer CenterOrange, CAOpen Hospital Dossier ->
Children's National Medical CenterWashington D.C, DCOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI